PLSE
HealthcarePulse Biosciences, Inc.
$14.60
+$1.21 (+9.04%)
Jan 5, 2026
Price History (1Y)
Analysis
Pulse Biosciences, Inc. is a healthcare company operating in the medical instruments and supplies industry. The company has a market capitalization of $989.41 million, revenue of $86,000 (TTM), and approximately 75 employees. The financial health of Pulse Biosciences, Inc. is characterized by significant losses. The company's net income (TTM) was -$74,733,000, with an EBITDA of -$77,848,000 and a free cash flow of -$23,174,876. Additionally, the company reported negative margins: gross margin of -224.4%, operating margin of -23682.6%, and profit margin of 0.0%. The returns on equity (ROE) was -87.0% and return on assets (ROA) was -48.9%. The balance sheet shows $95.21 million in cash and $7.89 million in debt, resulting in a debt-to-equity ratio of 8.51. The valuation context for Pulse Biosciences, Inc. is marked by a negative forward P/E ratio of -16.22 and an EV/EBITDA of -10.53. The price to book was 10.67 and the price to sales was 11504.73.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Visit website →Key Statistics
- Market Cap
- $989.41M
- P/E Ratio
- N/A
- 52-Week High
- $25.00
- 52-Week Low
- $12.56
- Avg Volume
- 166.80K
- Beta
- 1.69
Company Info
- Industry
- Medical Instruments & Supplies
- Exchange
- NCM
- Country
- United States
- Employees
- 75